Duality Advisers, LP Seagen Inc. Transaction History

Duality Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$117.37 - $139.17 $3.64 Million - $4.32 Million	-31,040 Reduced 80.89%	7,335 $942,000
Q3 2022 Nov 03, 2022	BUY	$135.27 - $180.11 $5.19 Million - $6.91 Million	38,375 New	38,375 $5.25 Million
Q2 2022 Aug 08, 2022	SELL	$108.81 - $179.33 $325,341 - $536,196	-2,990 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$119.61 - $157.85 $2.92 Million - $3.85 Million	-24,404 Reduced 89.09%	2,990 $431,000
Q4 2021 Feb 02, 2022	BUY	$142.57 - $190.86 $3.91 Million - $5.23 Million	27,394 New	27,394 $4.24 Million
Q3 2021 Nov 08, 2021	SELL	$142.45 - $169.82 $3.26 Million - $3.89 Million	-22,920 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$135.08 - $161.1 $2.05 Million - $2.45 Million	15,202 Added 196.97%	22,920 $3.62 Million
Q1 2021 May 13, 2021	SELL	$137.51 - $190.8 $600,918 - $833,796	-4,370 Reduced 36.15%	7,718 $1.07 Million
Q4 2020 Feb 09, 2021	BUY	$164.63 - $211.93 $1.99 Million - $2.56 Million	12,088 New	12,088 $2.12 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.